BNP Paribas Financial Markets
LENZ

BNP Paribas Financial Markets’s LENZ Therapeutics LENZ Stock Holding History

BNP Paribas Financial Markets’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$231K Buy
40,672
+35,824
+739% +$289K ﹤0.01% 4165
2026
Q1 		$44.4K Buy
4,848
+713
+17% +$10K ﹤0.01% 4760
2025
Q4 		$66.2K Buy
4,135
+613
+17% +$17.9K ﹤0.01% 4561
2025
Q3 		$164K Buy
3,522
+1,571
+81% +$57.8K ﹤0.01% 4098
2025
Q2 		$57.2K Buy
1,951
+944
+94% +$25.7K ﹤0.01% 4206
2025
Q1 		$25.9K Sell
1,007
-782
-44% -$19.3K ﹤0.01% 4464
2024
Q4 		$51.6K Sell
1,789
-859
-32% -$26.2K ﹤0.01% 4415
2024
Q3 		$62.9K Sell
2,648
-13,822
-84% -$307K ﹤0.01% 3571
2024
Q2 		$285K Buy
16,470
+249
+2% +$4.35K ﹤0.01% 2956
2024
Q1 		$362K Buy
+16,221
New +$337K ﹤0.01% 3014
2022
Q4 		– Sell
-45
Closed -$989 – 4698
2022
Q3 		$989 Buy
+45
New +$1.07K ﹤0.01% 4430

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Financial Markets's LENZ Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its LENZ Therapeutics (LENZ) stake by 739% in Q2 2026, buying an estimated $289K and bringing the position to 40,672 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #4165.

BNP Paribas Financial Markets first reported a position in LENZ in Q3 2022 and has held it in 11 quarters since. The position peaked at $362K in Q1 2024. 129 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • BNP Paribas Financial Markets held 40,672 shares of LENZ Therapeutics worth $231K as of Q2 2026.
  • BNP Paribas Financial Markets bought 35,824 LENZ Therapeutics shares in Q2 2026, an estimated $289K.
  • LENZ Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4165 holding.
  • BNP Paribas Financial Markets first reported a position in LENZ Therapeutics in Q3 2022 and has held it in 11 quarters since.
  • BNP Paribas Financial Markets's LENZ Therapeutics position peaked at $362K in Q1 2024.
  • 129 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.